Amphastar Pharmaceuticals, INC

Amphastar Pharmaceuticals reported mixed Q1 2026 results, with flat net revenues but a significant drop in GAAP net income and adjusted non-GAAP net income, alongside increased R&D spending.

Amphastar Pharmaceuticals' Board of Directors authorized a $50 million increase to its share buyback program to offset equity compensation dilution.

Amphastar Pharmaceuticals, Inc. announced new executive employment agreements for Jacob Liawatidewi and Rong Zhou, detailing compensation, severance, and change-in-control provisions.

Amphastar Pharmaceuticals, Inc. disclosed new and amended agreements with related parties for chemical intermediates supply and research services, involving family members of its top executives.

Amphastar Pharmaceuticals announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, highlighting BAQSIMI's continued growth and new product approvals amidst overall revenue decline.

Amphastar Pharmaceuticals announced an exclusive licensing agreement with Nanjing Hanxin for AMP-110, a synthetic corticotropin compound targeting inflammatory and autoimmune conditions, involving an upfront payment and significant milestone opportunities.

Amphastar Pharmaceuticals reports mixed Q1 2026 results with revenue flat, but gross profit down 18% due to increased costs and pricing pressures.

Amphastar Pharmaceuticals reports mixed Q3 2025 results with strong BAQSIMI sales growth offset by increased litigation expenses and declines in other key products.

Amphastar Pharmaceuticals reports a decline in net income and total revenues for Q2 2025, driven by product mix changes and increased operating expenses, despite strong BAQSIMI growth.

Amphastar Pharmaceuticals' Q1 2025 results show a slight decrease in total net revenues but a significant increase in BAQSIMI sales following the assumption of full global distribution.

Amphastar Pharmaceuticals saw a revenue increase in Q3 2024, driven by the integration of BAQSIMI and growth in key product sales, despite some margin pressures.

Amphastar Pharmaceuticals saw a significant increase in revenue and profitability in the second quarter of 2024, driven by the acquisition of BAQSIMI and strong performance in key product lines.

Amphastar Pharmaceuticals, Inc. reported a slight revenue decline in 2025 to $719.9 million, down 2% from 2024, with net income decreasing to $98.1 million, while launching new products and expanding its pipeline.

Amphastar Pharmaceuticals announces increased net revenues and net income for 2024, fueled by BAQSIMI, Primatene MIST, and other key products.

Amphastar Pharmaceuticals reports a significant increase in net revenues and net income for 2023, fueled by strong sales of key products and the acquisition of BAQSIMI.

Anthony T Pierce, a Director of Amphastar Pharmaceuticals, Inc., reported multiple transactions in common stock on July 9, 2026.

Director Richard K. Prins reported a gift of common stock and the acquisition of restricted stock units and options in Amphastar Pharmaceuticals.

Director Howard Lee acquired restricted stock units and stock options while disposing of shares to cover tax obligations.

Director Michael A. Zasloff acquired 8,143 restricted stock units and 17,365 stock options in Amphastar Pharmaceuticals.

Director Diane Gerst acquired 8,143 restricted stock units and 17,365 stock options as part of an annual equity compensation grant.

Director David Russell Gaugh was granted 8,143 restricted stock units and 17,365 stock options by Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 1, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Amphastar Pharmaceuticals has scheduled its 2025 Annual Meeting for June 2, 2025, and is seeking stockholder votes on the election of directors, ratification of auditors, executive compensation, and amendments to the company's certificate of incorporation.

Amphastar Pharmaceuticals will hold its 2025 annual meeting virtually on June 2, 2025, to vote on director elections, auditor ratification, executive compensation, and amendments to the certificate of incorporation.

Amphastar Pharmaceuticals issues a supplement to its proxy statement to correct an error in the voting standard for the proposed amendment and restatement of its 2015 Equity Incentive Plan.

Amphastar Pharmaceuticals has filed a definitive proxy statement with the SEC.

Amphastar Pharmaceuticals is holding its annual meeting to vote on key proposals including director elections, auditor ratification, executive compensation, and an amendment to its equity incentive plan.

Dimensional Fund Advisors LP has disclosed a beneficial ownership stake of 5.2% in Amphastar Pharmaceuticals Inc., holding 2,305,107 shares.

The Vanguard Group has filed an amended Schedule 13G for Amphastar Pharmaceuticals Inc., reporting zero beneficial ownership following an internal realignment.

BlackRock, Inc. has reported an increased beneficial ownership of 11.5% in Amphastar Pharmaceuticals, Inc., holding 5,333,463 shares of common stock.

Jack Y. Zhang, Mary Z. Luo, and Applied Physics & Chemistry Laboratories, Inc. (APCL) have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 24.8% of Amphastar Pharmaceuticals, Inc.'s common stock as of December 31, 2024.